Adam Brentnall

Dr. Adam Brentnall is a Senior Lecturer in Biostatistics at Queen Mary University of London's Wolfson Institute of Population Health. He holds a fellowship with the Digital Environment Research Institute (DERI) and collaborates closely with the Centre for Prevention, Detection and Diagnosis. His research focuses on cancer prevention and early detection, particularly breast and ovarian cancers, emphasizing risk stratification through statistical methodology and clinical trial design.

He co-leads a research methods module for MSc programmes at Barts Cancer Institute and has contributed to operational research in retail finance and aircraft scheduling. Current roles include membership on NICE's Ovarian Cancer Guidelines Committee, Cancer Research UK's Expert Review Panel for Early Detection Trials, and multiple clinical trial steering committees as a statistician.

His expertise spans statistical validation of risk models, cost-effectiveness analysis of preventive strategies, and interdisciplinary collaboration in biomedical research. He actively contributes to NHS-Galleri trial optimization, HPV screening protocols, and cancer susceptibility gene evaluation.

• Specializes in breast/ovarian cancer risk assessment and prevention
• Designs and analyzes clinical trials and epidemiological studies
• Advances AI-driven risk stratification techniques
• Focuses on healthcare equity and minority population interventions

Key collaborations involve Barts Cancer Institute, Cancer Research UK, and NIHR School for Primary Care Research. His work bridges methodological innovation with real-world healthcare applications.